Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada

The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, John Paul, Ding, Philip Q., Dolley, Aastha, Cheung, Winson Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528038/
https://www.ncbi.nlm.nih.gov/pubmed/37754496
http://dx.doi.org/10.3390/curroncol30090581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528038/
https://www.ncbi.nlm.nih.gov/pubmed/37754496
http://dx.doi.org/10.3390/curroncol30090581

Ejemplares similares